Serum-tryptase at diagnosis: a novel biomarker improving prognostication in Ph(+) CML.

about

The underestimated role of basophils in Ph chronic myeloid leukaemia

P2860

Q58798189-2C15AE05-10EF-43CD-B650-6CB2DF7FE388

P2860

Serum-tryptase at diagnosis: a novel biomarker improving prognostication in Ph(+) CML.

Item

http://www.wikidata.org/entity/Q41515301

description

2014 nî lūn-bûn

@nan

2014年の論文

@ja

2014年論文

@yue

2014年論文

@zh-hant

2014年論文

@zh-hk

2014年論文

@zh-mo

2014年論文

@zh-tw

2014年论文

@wuu

2014年论文

@zh

2014年论文

@zh-cn

name

Serum-tryptase at diagnosis: a novel biomarker improving prognostication in Ph(+) CML.

@en

type

Item

label

Serum-tryptase at diagnosis: a novel biomarker improving prognostication in Ph(+) CML.

@en

prefLabel

Serum-tryptase at diagnosis: a novel biomarker improving prognostication in Ph(+) CML.

@en

P1476

Serum-tryptase at diagnosis: a novel biomarker improving prognostication in Ph(+) CML.

@en

P2093

Christian Sillaber

http://www.w3.org/2001/XMLSchema#string

Michael Kundi

http://www.w3.org/2001/XMLSchema#string

Peter Valent

http://www.w3.org/2001/XMLSchema#string

Susanne Herndlhofer

http://www.w3.org/2001/XMLSchema#string

Wolfgang R Sperr

http://www.w3.org/2001/XMLSchema#string

P2860

Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia

Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia

Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome.

Nilotinib (formerly AMN107), a highly selective BCR-ABL tyrosine kinase inhibitor, is active in patients with imatinib-resistant or -intolerant accelerated-phase chronic myelogenous leukemia.

Early prediction of success or failure of treatment with second-generation tyrosine kinase inhibitors in patients with chronic myeloid leukemia

Serum tryptase levels in patients with mastocytosis: correlation with mast cell burden and implication for defining the category of disease.

Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia.

Clinical utility of tryptase levels in systemic mastocytosis and associated hematologic disorders.

Evolving concepts in the management of chronic myeloid leukemia: recommendations from an expert panel on behalf of the European LeukemiaNet.

Nilotinib in imatinib-resistant or imatinib-intolerant patients with chronic myeloid leukemia in chronic phase: 48-month follow-up results of a phase II study.

P304

354-362

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Christine Mannhalter

Gregor Hoermann

Thomas Pfeiffer

P577

2014-12-15T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

25628944

http://www.w3.org/2001/XMLSchema#string

P921

biomarker

P932

4300686

http://www.w3.org/2001/XMLSchema#string

Serum-tryptase at diagnosis: a novel biomarker improving prognostication in Ph(+) CML.

about

P2860

P2860

Serum-tryptase at diagnosis: a novel biomarker improving prognostication in Ph(+) CML.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P433

P478

P50

P577

P698

P921

P932

P1433

P1476

P2093

P2860

P304

P31

P433

P478

P50

P577

P698

P921

P932